We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AKYNZEO IV (Mundipharma Pty Ltd)
Product name
AKYNZEO IV
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
172 working days (255)
Active ingredients
fosnetupitant chloride hydrochloride
Registration type
EOI
Indication
New Combination
AKYNZEO IV (powder for injection) is indicated for:
- The prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
- The prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.